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nthony N. DeMaria, MD
eneral echocardiography. Although attention has re-
ently focused upon the left atrium as a marker of the
hronic state of left ventricular (LV) filling pressures, the
elationship between left atrial volume and diastolic dys-
unction has not been clearly defined. Pritchett et al. (1)
elated left atrial volume to progressive grades of diastolic
ysfunction (I to IV) in a group of subjects45 years of age
rom Olmsted County, Minnesota. They found that left
trial volume increased with worsening grades of diastolic
ysfunction and that diastolic dysfunction of grades III and
V were associated with a 62% increase in left atrial volume.
ith receiver-operator characteristics curves, they observed
n area under the curve of 0.81 and 0.98 for grade II and
rade III to IV diastolic dysfunction, respectively. Thus, this
ork established a clear relationship between diastolic
ysfunction and an increase in left atrial volume. Olshansky
t al. (2) evaluated the association between a variety of
arameters derived from transthoracic echocardiography
nd recurrent atrial fibrillation (AF) and/or stroke in the
trial Fibrillation Follow-up Investigation of Rhythm
anagement (AFFIRM) study. Their analysis revealed that
duration of qualifying AF episode of 48 h and an
ncreased left atrial diameter were associated with a greater
isk of recurrent AF. The hazard ratio for recurrent AF was
.21, 1.16, and 1.32 for mild, moderate, and severe enlarge-
ent, respectively. Thus, left atrial size is a risk factor for
ecurrent AF. In another study relating echocardiographic
ndings to cardiac arrhythmia, investigators from the Mul-
idisciplinary Study of Right Ventricular Dysplasia reported
n the findings in patients who met criteria for arrhythmo-
enic right ventricular dysplasia (ARVD) as defined by the
ask Force (3). They observed a significant increase in right
entricular and right atrial dimensions as well as a reduction
n right ventricle fractional area change in probands versus
ontrol subjects. The right ventricular outflow tract
RVOT) was the most commonly enlarged area, and an
VOT long axis diastolic dimension of 30 mm occurred
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Manuscript received November 11, 2005, accepted November 11, 2005.n 89% of ARVD patients. In an accompanying editorial,
cheinman and Crawford (4) commented that the diagnosis
f ARVD remains problematic and that this current study is
n important step in clarifying the criteria for the echocar-
iographic diagnosis. Finally, a study by Grayburn et al. (5)
eported upon the echocardiographic predictors of outcome
n patients with advanced heart failure due to systolic
ysfunction in the Beta-blocker Evaluation Survival Trial
BEST). In a careful assessment of echocardiograms per-
ormed in this trial, the authors observed that only LV
nd-diastolic volume index predicted death, with a thresh-
ld value for risk of 120 ml/m2. Mitral deceleration time
nd vena contracta of a mitral regurgitant jet were predictive
f the combined end point of death, heart failure hospital
tay, and transplantation. These data further delineate the
alue of echocardiography in the risk stratification of pa-
ients with heart failure.
issue Doppler and strain. Considerable efforts continue
o be devoted to the field of tissue Doppler recordings and
he measurements of LV strain that can be derived from
hem. Yu et al. (6) described a novel tool to assess LV
ystolic asynchrony that could be applied to the identifica-
ion of responders of cardiac resynchronization therapy. The
ew method, termed tissue synchronization imaging, trans-
orms the timing of regional peak velocities into color codes
hat enables immediate visual identification of systolic
ontractile delays in orthogonal walls. The authors applied
his methodology and found that tissue synchronization
maging allowed quick recognition of asynchronous areas
hat could then be assessed for time to peak systolic velocity
o as to predict the likelihood of reverse remodeling in
esponse to cardiac resynchronization therapy. The same
nvestigators evaluated whether strain rate imaging derived
rom tissue Doppler recordings could reliably distinguish
ransmural from nontransmural myocardial infarction (MI)
7). In a group of 47 consecutive patients, they compared
ata obtained by strain rate imaging with that provided by
ontrast-enhanced magnetic resonance imaging (MRI) us-
ng the delayed enhancement technique. Peak systolic strain
ate was significantly lower in transmural infarction seg-
ents than in non-transmural segments, and a cutoff value
or strain rate 0.59 s1 detected transmural infarction
ith a sensitivity of 90% and a specificity of 96%. Thus, the
eadily available tool of strain rate imaging can be of value in
istinguishing transmural from non-transmural infarction.
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January 1, 2006:184–202 Highlights of the Year in JACC 2005The assessment of myocardial tissue velocities has tradi-
ionally been based upon conventional Doppler techniques;
owever, a new methodology consisting of ultrasound
peckle tracking by two-dimensional imaging has recently
een developed. Notomi et al. (8) validated this speckle
racking imaging to accurately assess ventricular torsion in
omparison with tagged MRI and Doppler tissue imaging.
good correlation was observed between speckle tracking
nd MRI (r  0.93) that was slightly superior to the
orrelation with Doppler tissue imaging (0.76). Thus, two-
imensional ultrasound speckle tracking provides an impor-
ant new technique for the assessment of myocardial veloc-
ties and ventricular torsion.
hree-dimensional echocardiography. Three-dimensional
chocardiography continues to find important applications
n addressing physiological issues. Watanabe et al. (9) used
hree-dimensional echo techniques to quantify mitral valve
enting in patients with ischemic mitral regurgitation. They
bserved three-dimensional geometric deformity of the
itral leaflets and annulus in patients with ischemic mitral
egurgitation, helping to clarify the mechanism and point to
he diagnostic utility of the technique. With a broad beam
pectral Doppler transducer similar to that employed for
hree-dimensional echocardiography, Buck et al. (10) exam-
ned the vena contracta as an approach to quantify mitral
egurgitation and correlated regurgitant stroke volume by
his method to MRI in 24 patients with r  0.93. Thus,
road-beam spectral Doppler methods of quantifying the
ena contracta show promise as a technique to measure
egurgitant stroke volume in mitral regurgitation.
ypertrophic cardiomyopathy. Hypertrophic cardiomy-
pathy continues to be the object of intense interest among
ardiologists. Controversy continues regarding the optimal
herapeutic approach in patients with refractory symptoms.
mmen et al. (11) reported the long-term effects of surgical
eptal myectomy upon survival in 1,337 patients with
ypertrophic cardiomyopathy, 289 of whom underwent
urgical myectomy. In this retrospective study, they dem-
nstrated that surgical septal myectomy performed to relieve
utflow obstruction and symptoms in hypertrophic cardio-
yopathy was associated with a long-term survival equiva-
ent to that of the general population and superior to that of
bstructive cardiomyopathy without operation. In an ac-
ompanying editorial, Watkins and McKenna (12) com-
ent that, although no randomized data yet exist, the report
y Ommen et al. (11) could be interpreted as evidence that
urgical relief of obstruction improves long-term survival in
dults. An additional issue that has attracted attention
oncerns the transition of hypertrophic cardiomyopathy to a
ilated-hypokinetic form. Biagini et al. (13) reported on a
otal of 222 consecutive hypertrophic cardiomyopathy adult
atients who were prospectively followed for a mean of 11
9 years. Twelve patients evolved dilated-hypokinetic
entricle for an incidence of 5.3 per 1,000 patient years.
hese patients were younger at first evaluation, more often
ad a family history of hypertrophic cardiomyopathy or pudden death, and showed a greater interventricular septal
nd posterior wall thickness. Cardiovascular survival was
ower among these dilated-hypokinetic patients. In an
ccompanying editorial, Ommen (14) commented that the
ropensity to presentation at a young age and greater
ypertrophy support the concept that energetic crisis and
ltimate energetic failure may lead to the late-stage trans-
ormation from hypertrophy to dilatation.
alvular heart disease. The value of vasodilator therapy in
he prophylactic treatment of patients with aortic regurgi-
ation was the subject of intense investigation in the past
ear. Scognamiglio et al. (15) reported on the ten-year
ollow-up of their initial cohort of 266 patients with aortic
egurgitation undergoing aortic valve replacement, 134 of
hom had previously been treated with nifedipine and 132
ith placebo. Although the interval to surgery was longer in
he nifedipine-treated patients, operative mortality was
imilar, and ejection fraction normalized in these patients
hereas it remained abnormal in 28% of the placebo control
roup. At 10 years of follow-up, the nifedipine-treated
roup continued to manifest a higher ejection fraction (62%
s. 48%, p  0.001) and a higher survival (85% vs. 78%)
han control subjects. In an accompanying editorial,
ashore (16) commented that these data imply that nifed-
pine afterload reduction induces a benefit that persists long
fter the aortic regurgitation is resolved, even in those with
n abnormal ventricle.
ntravascular ultrasound (IVUS). The last year witnessed
esurgence of interest in IVUS. The technique was applied
y Hong et al. (17) to define the site of plaque rupture in all
hree native coronary vessels in patients with acute coronary
yndrome (ACS). Their data demonstrated that plaque
uptures occurred primarily in the proximal segments of the
eft anterior descending artery (LAD) and the proximal and
istal segments of the right coronary artery while occurring
hroughout the circumflex. These data could potentially
ave significance for the application of percutaneous inter-
ention. Two studies evaluated new techniques by which to
ssess the tissue characteristics of coronary plaques. Ka-
asaki et al. (18) derived integrated backscatter values using
adiofrequency signals from a 40-MHz IVUS catheter.
hree-dimensional reconstruction and color coded mapping
ere then performed. Plaques were displayed in terms of
brous volume, lipid volume, and mixed lesions. They
emonstrated that statin therapy reduced the lipid compo-
ent in patients with stable angina without reducing the
egree of stenosis. Murashige et al. (19) applied wavelet
nalysis of radiofrequency IVUS signals to detect lipid laden
laque. As compared with histology, wavelet analysis en-
bled in vitro as well as in vivo detection of lipid laden
laque, a characteristic associated with vulnerability. Finally,
VUS was applied in two multicenter studies assessing
oronary vasculopathy among heart transplant recipients
20,21). The studies, in which patient populations may have
verlapped, yielded similar results and demonstrated that
rogression of intimal thickness 0.5 mm in the first year
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Highlights of the Year in JACC 2005 January 1, 2006:184–202fter transplantation seems to be a reliable surrogate marker
or subsequent mortality, non-fatal major adverse cardiac
vents (MACE), and the development of angiographic
oronary artery vasculopathy through five years after trans-
lantation.
ontrast echocardiography. Progress continues in the de-
elopment of contrast echocardiographic methodology as
ell as the application of contrast echo in the clinical
etting. In a report dealing with spontaneous echo contrast,
ernhardt et al. (22) prospectively performed 12-month
ollow-up transesophageal echocardiography and cerebral
RI in patients with AF. The findings in 128 patients with
ense spontaneous contrast were compared with those of
43 patients with faint spontaneous contrast. During
ollow-up, six patients died owing to embolic events and 19
15%) patients with dense contrast exhibited MRI evidence
f silent embolism. Patients with events were also observed
o have lower left atrial appendage peak emptying velocities.
hus, this study demonstrated that silent embolization was
urprisingly frequent in patients with dense spontaneous
cho contrast. In an accompanying editorial, Goldman et al.
23) commented that this study reinforces the dangers of
F, even with apparent anticoagulation, and points to dense
pontaneous contrast as an important risk factor for events.
Although myocardial contrast echocardiography (MCE)
o study perfusion has been the object of much clinical
nvestigation, clinical applications have not yet clearly
merged. In a very large study, Tong et al. (24) compared
CE in nearly 1,000 patients presenting to the emergency
oom with chest pain and a nondiagnostic electrocardio-
ram (ECG) with the Thrombolysis In Myocardial Infarc-
ion (TIMI) risk score to predict adverse events. Myocardial
ontrast echocardiography was performed by standard
ethods in the emergency room, and patients were followed
or 24-h and 30-day events including death, MI, unstable
ngina, or revascularization. Only 2 of 523 patients with
ormal regional contractile function by echo had a primary
vent, and myocardial perfusion further classified these
atients into intermediate and high risk groups. These
esults were superior to the TIMI score for risk stratifica-
ion. In an accompanying editorial, Vannan et al. (25)
ointed to the challenges of implementing MCE in the
mergency room as well as the important economic consid-
rations; however, they indicated that these data demon-
trate that MCE may play a unique role in the identification
f myocardial ischemia in patients presenting to the emer-
ency room. The use of MCE in conjunction with stress
esting presents issues in addition to those for contrast echo
erformed at rest, particularly with regard to feasibility and
afety. Tsutsui et al. (26) performed dobutamine stress
CE in 1,486 patients over four years with a variety of
gents and instruments. They found that MCE was feasible
or analysis of 95% of wall segments at peak stress and
ielded a higher accuracy for detecting patients with angio-
raphically significant coronary disease than analysis of wall
otion (84% vs. 66%; p  0.001). No increased incidence Sf arrhythmias was observed with the contrast agent. Thus,
hese data attest to the suitability of dobutamine stress
CE for clinical application. Finally, MCE was assessed as
possible method to provide measurements of the elusive
arameter of absolute myocardial blood flow. Vogel et al.
27) first validated an algorithm to derive myocardial blood
ow from contrast echocardiography in vitro. Subsequently,
hey performed studies in healthy volunteers and patients
ith coronary artery disease (CAD). They found a linear
elationship between measures of myocardial blood flow by
CE and positron emission tomography (R2  0.88) and
good correlation between the methods in regard to
oronary flow reserve in patients with CAD (r2  0.73).
hus, these very promising data suggest that MCE may be
apable of providing clinical information regarding absolute
yocardial blood flow.
NTERVENTIONAL CARDIOLOGY
otirios Tsimikas, MD
rug-eluting stents (DES). SIROLIMUS VERSUS PACLI-
AXEL. The TAXi trial (28) was a single-center study that
andomized 202 patients to sirolimus-eluting stents (SES)
ersus paclitaxel-eluting stents (PES) in an unselected and
elatively high-risk population. Follow-up was limited to
linical events at seven months; the study showed a MACE
nd target lesion revascularization (TLR) rate of 6% and
%, respectively, in the SES group and 4% and 2%,
espectively, in the PES group, with no statistical differences
etween groups. This was the first randomized trial to
eport comparisons between DES. The clinical outcomes of
atients treated with SES (n  508) and PES (n  576)
ere evaluated in unselected patients treated in two sequen-
ial prospective registries at the Rotterdam Cardiology
ospital (29). At one year, outcomes were not significantly
ifferent, with MACE rates of 13.9% in the PES group and
0.5% in the SES group and target vessel revascularization:
.4% versus 3.7%, respectively. The trends toward higher
rude rates with PES were explained by higher baseline risk
n the PES group.
TENT THROMBOSIS. The issue of stent thrombosis (ST)
fter implantation of DES has received significant attention
n the past year, owing to the significant mortality associated
ith it and reports documenting late stent thrombosis (30
ays after stent implantation), particularly after withdrawal
f anti-platelet therapy. In a meta-analysis of 10 random-
zed trials comparing bare-metal stents (BMS; n  2,602)
ith SES and PES (n  2,428), Moreno et al. (30) showed
hat the incidence of ST was not increased in patients
eceiving DES (0.58% vs. 0.54% for BMS; p 1.0) and was
imilar between patients receiving SES or PES (0.57% vs.
.58%). The clinical follow-up was 9 to 12 months, and
atients with PES received a mean of 4.2 months of
lopidogrel versus 2 months for SES and 1 month for BMS.
ix of 15 of the DES thromboses occurred beyond 30 days
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January 1, 2006:184–202 Highlights of the Year in JACC 2005nd were strongly associated with absence of thienopyridine
herapy and stent length. These results were generally
choed by those of Bavry et al. (31), who performed an
ndependent meta-analysis evaluating eight randomized tri-
ls of PES versus BMS.
Additional data from the Rapamycin-Eluting Stent Eval-
ated at Rotterdam Cardiology Hospital (RESEARCH)
egistry comprising three sequential cohorts of 506 consec-
tive patients with BMS, 1,017 consecutive patients with
ES, and 989 consecutive patients treated with PES,
eflecting an unselected population, showed that the 30-day
ncidence of ST was 1.4% (n  6) in BMS, 1.5% (n  15)
n SES, and 1.6% (n  16) in PES (32). Bifurcation
tenting in the setting of acute myocardial infarction (AMI)
as a strong independent risk factor for ST (odds ratio 12.9,
 0.001). Follow-up (mean 1.5 years) of this group of
atients showed eight (0.35%) cases of late angiographic
tent thrombosis, three with SES (at 2, 25, and 26 months),
nd five with PES (at 6, 7, 8, 11, and 14.5 months) (33).
hree cases were related to complete cessation of antiplate-
et therapy; two cases occurred after cessation of clopidogrel
ut receiving aspirin therapy, and three cases occurred while
eceiving aspirin monotherapy. Interestingly, there were no
ases of late angiographic stent thrombosis in patients
eceiving dual antiplatelet therapy.
Several studies evaluated the mechanisms behind these
bservations. Ajzenberg et al. (34) showed that shear-
nduced platelet aggregation was significantly increased in
atients suffering ST compared with patients without stent
hrombosis and normal volunteers. Wenaweser et al. (35)
lso showed that resistance to aspirin therapy, measured by
denosine-diphosphate platelet aggregation, was present in
atients with previous stent thrombosis. Both of these
tudies were small and retrospective and were carried out in
atients with BMS. Nonetheless, they support the notion
hat certain patients are at inherently higher risk of ST.
sing IVUS, Fujii et al. (36) showed that patients with ST
end to have stent under-expansion and residual reference
egment stenosis, further implicating procedural factors in
T.
FFICACY OF DES IN VARIOUS CLINICAL SCENARIOS. In
nprotected left main CAD, Park et al. (37) performed SES
lacement in 102 consecutive patients with preserved LV
unction and compared the results with 121 patients treated
ith BMS. There were no incidents of death, stent throm-
osis, Q-wave MI, or emergent bypass surgery during
ospital stay in either group. At six-month angiographic
ollow-up, the SES group showed a lower late lumen loss
0.05 mm vs. 1.27 mm, p  0.001) and a lower restenosis
ate (7.0% vs. 30.3%, p  0.001) compared with the BMS
roup. At 12 months, the rate of freedom from death, MI,
nd TLR was 98.0% in the SES group and 81.4% in the
MS group (p  0.0003). These results are better than one
ould have predicted. rIn saphenous vein grafts, Ge et al. (38) evaluated the
n-hospital and six-month clinical and angiographic out-
omes of DES implantation in 61 consecutive patients with
aphenous vein graft lesions and compared them with 89
onsecutive patients treated with BMS in the 24 months
mmediately before the introduction of DES. The rate of
n-hospital MACE was similar between the two groups, but
ix month MACE was 11.5% in the DES group and 28.1%
n the BMS group (p  0.02). The DES group had a
ignificantly lower incidence of in-segment restenosis
10.0% vs. 26.7%, p  0.03), TLR (3.3% vs. 19.8%, p 
.003), and target vessel revascularization (4.9% vs. 23.1%,
 0.003). Diabetes and age of saphenous vein graft were
ndependent predictors of MACE at six-month follow-up.
In diabetes mellitus, women, ACS, and left anterior
escending lesion subgroups, the TAXUS IV trial evaluated
ES versus BMS in 1,314 patients undergoing elective
ercutaneous coronary intervention (PCI) of de novo coro-
ary lesions. Diabetes and women were pre-specified sub-
roup analyses. Medically treated diabetes was present in
18 patients (24%), 105 of whom required insulin.
aclitaxel-eluting stent reduced the rate of 9-month binary
ngiographic restenosis by 81%, TLR by 65%, target vessel
evascularization by 53%, and MACE by 44%. The one-
ear rates of cardiac death, MI, and subacute thrombosis
ere comparable between the groups. In the insulin-
equiring subgroup, the TAXUS stent reduced angiographic
estenosis by 82% and TLR by 68% (39). Women assigned
o PES had restenosis rates and late loss similar to men, but
igher absolute rates of TLR (7.6% vs. 3.2%, p  0.03),
rimarily owing to higher co-morbidities than men (40).
imilar benefits were noted in patients presenting with ACS
41) and treatment of the LAD (42). Furthermore, the need
or bypass surgery at one year was reduced among patients
andomized to PES (2.6% vs. 6.3%, p 0.02). The findings
or the LAD were further substantiated by Seung et al. (43),
ho showed similar benefits compared with BMS. Al-
hough these studies show improved clinical benefits with
ES, they were not necessarily powered to evaluate differ-
nces between groups and were also not randomized.
ELATIONSHIP OF LATE LUMEN LOSS TO TLR. Ellis et al.
44) evaluated the relationship between angiographic late
oss and TLR in the TAXUS IV trial by defining the
elationship between in-stent and in-segment late loss, the
hape of the late loss histogram (variance and skewedness)
nd nine-month TLR. Late loss was closely related to TLR
or both PES and BMS both in-stent and in-segment. For
ndividual patients (mean reference vessel of 2.8 0.5 mm),
he probability of a 5% to 10% risk of TLR was not apparent
ntil in-segment late loss was0.50 to 0.65 mm. At greater
ate losses, the late loss TLR relationship was steep and
early linear. Higher rates of TLR were also related to
igher variance and skewedness. In an accompanying edi-
orial, Kereiakes et al. (45) suggest that the biological
elationship of angiographic late loss is different between
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Highlights of the Year in JACC 2005 January 1, 2006:184–202ES and BMS and more appropriate statistical methodol-
gy is required to analyze these relationships, particularly as
t relates to the mean late loss. They suggest that the
inimum difference in late loss between two different stents
nd its relationship to TLR is not known but may be
linically relevant when patients with higher rates of reste-
osis are studied, such as those with multivessel disease or
omplex lesions.
REATMENTOF BIFURCATION LESIONS. Bifurcation lesions
emain a challenging lesion subset in interventional cardi-
logy, and various techniques have been recently promoted
ith the use of DES. Ge et al. (46) reported the long-term
utcomes after implantation of DES in bifurcation lesions
ith the “crush” technique in 181 consecutive patients.
estenosis of the main branch was 11.5%, of the side branch
1.6%, and TLR was 14.9%. Three cases (1.7%) of intra-
rocedural stent thrombosis and five (2.8%) cases of post-
rocedural stent thrombosis occurred. Final kissing balloon
nflation was associated with more favorable long-term
utcomes. In this study, the improved rates of TLR over
istorical controls seemed to be diminished by the increased
isk of ST. Costa et al. (47) evaluated IVUS findings after
rush-stenting of bifurcation lesions and showed that the
ajority of side branch lesions were underexpanded, which
ould not be detected angiographically, and that incomplete
tent apposition was present in 60% of lesions. These
ndings suggest potential mechanisms for both restenosis
nd stent thrombosis. Future studies will evaluate dedicated
ifurcation stents, as was suggested by the Safety and
easibility of a Novel Dedicated Stent for the Treatment of
ifurcation Coronary Lesions (FRONTIER) stent registry
48), presumably with drug coatings.
UBLIC REPORTING OF PCI RESULTS. Moscucci et al. (49)
ompared demographics, indications, and outcomes of
1,374 patients included in an eight-hospital PCI database
n Michigan where no public reporting is present, with
9,048 patients in a statewide PCI database in New York,
here public reporting is present. Patients in Michigan
ore frequently underwent PCI for AMI and cardiogenic
hock and were generally higher risk than those in New
ork. The unadjusted in-hospital mortality rate was signif-
cantly lower in New York than in Michigan; however, after
djustment for co-morbidities, there was no significant
ifference in mortality between the two groups (adjusted
dds ratio 1.05, 95% confidence interval 0.84 to 1.31, p 
.70). The authors concluded that a case selection bias
riven by fear of public reporting of high mortality rates in
ew York may be a potential explanation for the differences
n case mix and mortality rates.
VUS STUDIES. Fassa et al. (50) determined that the lower
ange of minimal luminal area in normal left main coronary
rteries (n  121) was 7.5 mm2. Intravascular ultrasound
as then performed on 214 patients with angiographicallyndeterminate left main coronary arteries lesions with de- perral of revascularization if the minimal luminal area was
arger than 7.5 mm2. During a mean follow-up period of 3.3
2.0 years, there was no significant difference in MACE
etween patients with a minimal luminal area 7.5 mm2
ho underwent revascularization and those with a minimal
uminal area 7.5 mm2 deferred for revascularization. The
uthors concluded that IVUS is an accurate method to
ssess angiographically indeterminate left main coronary
rteries lesions and that deferring revascularization for
atients with a minimum lumen area 7.5 mm2 seemed to
e safe.
A second study demonstrated that IVUS examination of
ative coronary arteries does not result in an acceleration of
he atherosclerotic process (51).
ERIPHERAL ARTERIAL DISEASE: FEMOROPOPLITEAL DIS-
ASE. Scheinert et al. (52) performed a systematic X-ray
creening in 93 patients and showed that stent fractures
ere detected in 45 of 121 treated legs and 64 of 261 stents.
racture rates were 13.2% for stented length 8 cm, 42.4%
or stented length 8 to 16 cm, and 52.0% for stented
ength 16 cm. Restenosis was present at the site of stent
racture in 21 cases and occlusion in 22 cases. The primary
atency rate at 12 months was significantly lower for
atients with stent fractures. There is a considerable risk of
tent fractures after long segment femoral artery stenting,
hich is associated with a higher in-stent restenosis and
eocclusion rate.
ENAL ARTERY STENTING. Rocha-Singh et al. (53) enrolled
08 hypertensive patients with de novo or restenotic 70%
orto-ostial renal artery stenoses who underwent implanta-
ion of a balloon-expandable stent after unsuccessful percu-
aneous transluminal renal angioplasty. The nine-month
estenosis rate was 17.4% and systolic/diastolic blood pres-
ure was decreased. The 24-month cumulative rate of major
dverse events was 19.7%. This uncontrolled study suggests
hat renal artery stenting reduces the number of anti-
ypertensive medications and stabilizes the creatinine level.
ATENT FORAMEN OVALE AND MIGRAINE HEADACHE. Two
tudies were reported that suggest that closure of a patent
oramen ovale or atrial septal defect (ASD) reduces the
ncidence of migraine headache. Azarbal et al. (54) followed
9 adult patients who underwent transcatheter closure of a
atent foramen ovale/ASD. At three months after the
rocedure, migraine headache disappeared completely in
5% of patients with aura and in 31% of patients without
ura. Of the remaining patients, 40% had significant im-
rovement. Reisman et al. (55) followed 162 consecutive
atients with paradoxical cerebral embolism who underwent
ranscatheter patent foramen ovale closure for prevention of
ecurrent cryptogenic stroke or transient ischemic attack.
efore the procedure, migraine was present in 35% of
atients, and 68% experienced migraine with aura. Com-
lete resolution of migraine symptoms occurred in 56% of
atients, and 14% of patients reported a significant reduc-
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ional studies with a strong potential for placebo effect, they
et the stage for future randomized trials.
RACTIONAL FLOW RESERVE. Angiographic analysis of
ailed side branches after stent placement is suboptimal. Koo
t al. (56) evaluated 97 jailed side branch lesions (vessel size
2.0 mm, 50% diameter stenosis). No lesion with 75%
tenosis had fractional flow reserve 0.75. Among 73
esions with 75% stenosis, only 20 lesions were function-
lly significant. The authors concluded that fractional flow
eserve measurement in jailed side branch lesions is both
afe and feasible and suggests that most of these angio-
raphically significant lesions do not have functional
ignificance.
UCLEAR CARDIOLOGY, CARDIAC COMPUTED
OMOGRAPHY, AND CARDIOVASCULAR MAGNETIC
ESONANCE (CMR)
aniel S. Berman, MD
ingle-photon emission computed tomography (SPECT).
yocardial perfusion SPECT (MPS) has become one of
he most widely used cardiac imaging methods and plays a
entral role in guiding decisions regarding the need for
onsidering revascularization in patients with known or
uspected CAD. Perhaps the most important publication
egarding SPECT in 2005 was the American College of
ardiology Foundation/American Society of Nuclear Car-
iology Appropriateness Criteria for SPECT, representing
he first in a series of technical documents from the
merican College of Cardiology that will systematically
ategorize cardiovascular tests and procedures used by car-
iologists in daily practice. A 12-member technical panel of
iverse background considered a broad spectrum of poten-
ial indications, categorizing them as inappropriate, uncer-
ain, and appropriate. The results are expected to have a
ignificant impact on physician decision making and reim-
ursement policy (57).
To identify which asymptomatic diabetic patients are
andidates for screening with MPS, Rajagopalan et al. (58)
xamined 1,427 asymptomatic diabetic patients without
nown CAD who underwent MPS. High-risk findings on
tress MPS were present in 18% and were associated with a
.9% annual mortality rate. Of patients with high-risk MPS
ho had coronary angiography, 61% were found to have
igh risk angiographic findings. Electrocardiographic Q
aves and/or evidence of peripheral arterial disease identi-
ed the patients most suitable for screening.
Leslie et al. (59) reported prognostic value of lung uptake
f radioactivity in 718 patients undergoing stress 99mTc-
estamibi MPS who were followed up mean 5.6 years. The
tress lung-to-heart ratio (LHR) provided a small but
ignificant improvement in risk stratification when added to
linical, stress test, perfusion, and LV volume information
global chi-square 168.6 vs. 150.7, p  0.00001). Stress mHR is an adjunctive prognostic measure in patients with
nown or suspected CAD.
ositron emission tomography. Invasive angiographic as-
essments of coronary vasomotor function have demon-
trated that impairment of endothelium-related coronary
ow increases— endothelial dysfunction—independently
redicts future cardiovascular events. With 13N-ammonia
ositron emission tomography in 72 patients with normal
oronary angiograms, Schindler et al. (60) were the first to
emonstrate that impaired myocardial blood flow increases
n response to cold pressor testing—a noninvasive method
or assessing coronary endothelial dysfunction—are at in-
reased risk for cardiovascular events.
Patient outcome after myocardial viability assessment
emains a topic of clinical interest. Desideri et al. (61)
tudied 261 patients with ischemic cardiomyopathy, of
hom 167 were treated medically and 94 were revascular-
zed after undergoing F-18 fluorodeoxyglucose positron
mission tomography for assessment of viability. The car-
iac death rate was significantly less in the revascularized
atients compared with medically treated patients (13% vs.
4%, p  0.05). Medically treated patients with ischemic
ardiomyopathy and large areas of viable myocardium by
ositron emission tomography (20% of the LV) are at
igh risk for cardiac death.
oronary calcium. The year 2005 saw the publication of
everal studies documenting that the coronary artery calcium
s associated with cardiovascular disease events. In a pro-
pective, population-based study of 4,613 asymptomatic
articipants, Arad et al. (62) in the St. Francis Heart Study
valuated the relationships among coronary calcification,
oronary disease risk factors, c-reactive protein (CRP), and
therosclerotic cardiovascular disease events. During 4.3
ears, 119 had sustained at least one cardiovascular disease
vent (cardiac death, non-fatal MI, PCI, or stroke). Nearly
0% of the patients had coronary artery calcium scores
400, indicating advanced coronary atherosclerosis; in
hese patients, rates for CAD event was 3.26% per year. The
oronary artery calcium score predicted CAD events inde-
endently of standard risk factors and CRP (p  0.004),
as superior to the Framingham risk index in the prediction
f events (area under the ROC curve of 0.79 0.03 vs. 0.69
0.03, p  0.0006), and enhanced stratification of those
alling into the Framingham categories of low, intermediate,
nd high risk (p  0.0001). In an accompanying editorial,
rundy (63) noted that the coronary artery calcium mea-
urements seem to have clinical utility in the patients with
ntermediate risk (10% to 20% 10-year risk of coronary heart
isease death or MI) but not in other groups. It is antici-
ated that the increasing data will increase the degree of
cceptance of coronary artery calcium as a measurement that
s useful in guiding management decision in patients with
ntermediate risk.
Taylor et al. (64) reported similar findings in 2,000
ealthy men and women ages 40 to 50 years in active
ilitary duty. Coronary calcium was found in 22.4% of men
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Highlights of the Year in JACC 2005 January 1, 2006:184–202nd 7.9% of women. No events occurred in women,
ttributed to the young age of the study population. Coro-
ary calcium was associated with an 11.8-fold increased risk
or incident coronary heart disease (p  0.002) in a Cox
odel controlling for the Framingham risk score. The
arginal cost effectiveness, assuming a 30% improvement in
urvival associated with primary prevention among at-risk
en, was modeled to be $37,633 per quality-adjusted life
ear saved.
ultislice computed tomography (MSCT). Continued
dvances in MSCT imaging technology have resulted in
ncreasing interest from the cardiology community in cor-
nary computed tomography angiography, which promises
o become the first clinically accurate noninvasive coronary
rtery imaging method. In 2005, with the help of the
merican College of Cardiology, the Society of Cardiovas-
ular Computed Tomography was formed and by the fourth
uarter had over 1,000 members. Four manufacturers were
elivering 64-slice MSCT scanners in 2005, with spatial
esolution as low as 0.4 mm and rotation time as fast as 330
s. In one of the first correlative studies with a 64-slice
canner, Raff et al. (65) studied 70 consecutive patients
ndergoing invasive coronary angiography by using 64-slice
piral CT. In 935 (88%) of 1,065 segments, high correlation
as observed between quantitative CT assessment and
uantitative coronary angiography with a Spearman corre-
ation coefficient of 0.76 (p  0.0001). Bland-Altman
nalysis revealed minimal bias with mean difference in
ercent stenosis of 1.3  14.2%. Specificity, sensitivity, and
ositive and negative predictive values for the presence of
ignificant stenoses were: by segment (n  935), 86%, 95%,
6%, and 98%, respectively; by artery (n  279), 91%, 92%,
0%, and 97%, respectively; by patient (n  70), 95%, 90%,
3%, and 93%, respectively. The authors noted that patients
ith coronary artery calcium scores 400, heart rates over
0 beats/min, and obesity remain a challenge even with the
4-slice scanner.
Multislice computed tomography may become clinically
seful in the noninvasive diagnosis of in-stent restenosis. In
hat was reported as the first study of its type, Gaspar et al.
66) examined 65 patients with 111 coronary stents who had
SCT with a 40-slice scanner and were referred for repeat
nvasive coronary angiography. in-stent restenosis (60%
uminal narrowing by quantitative coronary angiography)
as found in 18 (16.2%) of the stented segments and in 16
24.6%) patients. Narrowing of the stented segment was
raded 1 to 4 according to the proportion of the vessel
umen that was poorly enhanced. The MSCT findings
orrelated with coronary restenosis, with restenosis in only 1
f 59 (1.6%) multidetector CT grade 1 segments, but in
ore than three-quarters (12 of 15, 80%) of multidetector
T grade 4 segments (sensitivity 72.2%, specificity 92.5%,
ositive predictive value 65.0%, negative predictive value
4.5%). Using MSCT grades 3 or 4 combined for resteno-
is, sensitivity of MSCT was 88.9%, specificity 80.6%.
lthough promising, the method currently is dependent not anly on the scanner used and issues such as heart rate but
lso on stent type, size, and location. Potentially already
seful to rule out in-stent restenosis in patients with some
ut relatively low clinical suspicion, this application will
evertheless require further refinement before it becomes a
outine clinical tool.
The ability of CT to assess myocardial viability in a
anner analogous to the delayed enhancement by CMR
as studied by Mahnken et al. (67). They compared
ontrast-enhanced 16-slice MSCT with contrast-enhanced
MR in 28 patients within two weeks after MI. There was
xcellent agreement between late-enhancement CMR and
ate-enhancement MSCT (kappa  0.878). Whereas the
mages did not appear to provide as high contrast as
bserved with CMR, the authors concluded that late-
nhancement MSCT seems to be as reliable as delayed
ontrast-enhanced CMR in assessing infarct size and myo-
ardial viability in AMI. This approach could prove useful
s an added procedure (at lower radiation dose) to CT
oronary angiography and in patients needing viability
ssessment but unable to undergo CMR.
MR. The potential of delayed enhancement CMR to
ssess myocardial infarct size can be of both clinical and
esearch importance. Ibrahim et al. (68) demonstrated that
n patients after AMI and successful reperfusion, infarct size
y CMR is stable over time and matches well with SPECT
erfusion defect. Thirty-three patients were examined by
elayed enhancement CMR and SPECT 7  2 days after
MI and successful coronary intervention. All patients
howed myocardial delayed enhancement in the infarct
egion. Delayed enhancement CMR MI extent was stable
ver time and agreed well with SPECT within an average
ifference of 3% of the LV myocardium. Contrast-
nhanced–MRI under standardized conditions can accu-
ately assess myocardial infarct size in vivo and may be
ttractive for serving as a surrogate end point early after
MI.
Already widely appreciated as clinically useful in assess-
ent of patients with MI, CMR is emerging as a useful tool
or assessing a variety of other cardiac conditions. As an
xample, a study by Abdel-Aty et al. (69) has shown that a
ombined approach with three CMR sequences (T2-
eighted imaging [edema], early and late gadolinium en-
ancement) provides a high diagnostic accuracy and is a
seful tool in the diagnosis and assessment of patients with
uspected acute myocarditis. In 25 patients with suspected
cute myocarditis and 23 healthy control subjects, the best
iagnostic performance was obtained when “any-two” of the
hree sequences were positive in the same patient yielding a
6% sensitivity, 95.5% specificity, and 85% diagnostic
ccuracy.
Cardiovascular magnetic resonance is an excellent tool for
lassifying heart failure patients with the presence or ab-
ence of underlying CAD. In patients with heart failure but
ithout clinical suspicion of CAD, CMR might offer a validlternative to coronary angiography for the detection of
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January 1, 2006:184–202 Highlights of the Year in JACC 2005AD. Soriano et al. (70) reported 71 patients with heart
ailure without history of MI, with neither Q waves nor
linical data suggesting CAD, undergoing both delayed
nhancement-CMR and coronary angiography. Twenty-
ne patients in the angiographically proven CAD group (21
f 26, 81%) showed subendocardial and/or transmural
nhancement, whereas only 4 of 45 (9%) in the unob-
tructed coronary arteries group had this finding (p 
.001).
Cardiovascular magnetic resonance also has the potential
o be effective in the noninvasive evaluation of human
therosclerotic plaques. With CMR, Yonemura et al. (71)
nvestigated the effects of 20-mg versus 5-mg atorvastatin
n thoracic and abdominal aortic plaques in 40 hypercho-
esterolemic patients who were randomized to receive either
ose. Treatment effects were evaluated as changes in vessel
all thickness and vessel wall area of atherosclerotic lesions
rom baseline to 12 months of treatment as assessed by
MR. The 20-mg dose induced a greater low-density
ipoprotein (LDL) cholesterol reduction than did the 5-mg
ose (47% vs. 34%, p  0.001). Notably, the degree of
laque regression in thoracic aorta correlated with LDL
holesterol (r 0.64) and CRP (r 0.49) reductions. They
oncluded that one-year 20-mg atorvastatin treatment in-
uced regression of thoracic aortic plaques with marked
DL cholesterol reduction and resulted in only retardation
f plaque progression in abdominal aorta.
ONGENITAL HEART DISEASE
avid Sahn, MD
ong-term results after primary one-stage repair of
ransposition of the great arteries and aortic arch ob-
truction. Two European groups reported on long-term
esults for the one-stage repair of transposition of the great
rteries and aortic arch obstruction (72). All coronary
atterns were dealt with, and in 97% of the cases, ventricular
eptal defect was repaired. The aortic arch was enlarged,
oth with a patch and autologous fixed pericardium in most
atients. Nine hospital deaths occurred in the first 24
onths. Ten-year survival was 76%, and 89% of those
urviving required no other interventions. Re-coarctation
ccurred in 3 of the 29 survivors and was treated by catheter
ntervention. Complex coronary patterns associated with
ide by side great arteries in these patients and severe
ulmonary hypertension were other risk factors. The results
how that a primary one-stage repair of severe aortic arch
bstruction in transposition is feasible and, especially for the
perations being performed more than 15 years ago, the
esults are impressive.
ssessment late after the arterial switch operation for
ransposition of the great arteries. Simone et al. (73)
ooked for evidence of overt fibrocellular intimal thickening
n twenty-two asymptomatic children who were enrolled a
edian of 8.6 years after an arterial switch procedure and
perated at a median age of 47 days. Of the 22 children pnrolled, 37 coronary arteries were studied by IVUS. Intimal
ndex in percentage was a mean of 11.7% in the most
arrowed segment and a mean of 5% for the osteal. Thirty
ercent of the arteries had moderate to severe vessel wall
bnormalities and a 6.4% mean reduction in volume of the
rteries. Intimal thickening was most often eccentric. Early
ndings of these coronary artery IVUS studies suggest a
eed to continue to follow this population of post arterial
witch population for their fibrocellular intimal proliferation
eaction and perhaps begin to consider CAD risk factor
ontrol strategies in this population.
A study in the same population looked at the vasomotor
unction of the epicardial coronary arteries in nineteen
symptomatic patients five to eight years after arterial switch
sing a Doppler flow wire during follow-up catheterization
nd coronary angiography (74). Coronary artery size did not
iffer between the two groups, but the diameter changes
easured during nitroglycerin bolus were blunted in the
ost-arterial switch group. Also during acetylcholine ad-
inistration, coronary flow reserve was lower in the arterial
witch patients. The arterial switch group had larger coro-
ary arteries and showed limited flow reserve as a function
f less dilation.
mpact of re-coarctation after the Norwood operation on
urvival in the balloon angioplasty era. Another impor-
ant surgical study followed re-coarctation patients after the
orwood procedure for hypoplastic left heart syndrome
erformed from 1986 through 2001 (75). Of the 954
atients who underwent Norwood, 633 survived more than
8 h. Re-coarctation occurred in 58%. The median age of
uspected obstruction was of 6.6 months; 35 underwent
alloon angioplasty for recurrent coarctation, thirty-one
fter the Norwood, and the other 4 after their completion of
avopulmonary anastomosis. Of the 35 balloon angioplasty,
2 yielded satisfactory results, reducing the residual grade
nto an average of 3.9 mm. Six patients had further
ecurrence and underwent re-dilation; freedom from re-
bstruction was 79% one in five years after the angioplasty.
he success rate for dealing with this not uncommon
omplication of the Norwood procedure suggests that the
ccurrence of obstruction at the aortic arch is common in
he first year and can be dealt with adequately by balloon
ngioplasty.
esynchronization therapy in pediatric and congenital
eart disease patients: an international multicenter
tudy. The important area of resynchronization treatment
or patients manifesting heart failure was studied by Dubin
t al. (76). A total of 103 patients were reviewed who were
ither21 years of age or who had congenital heart disease.
t 4.5 months of follow-up, mean QRS duration in these
atients decreased from 166 to 124 ms and ejection fraction
ncreased by a mean of 13% to 40  15%. There was no
elationship between ejection fraction and QRS duration
nd ejection fraction improvement. The congenital heart
isease group responded as well as the cardiomyopathy
atients. There were two adverse events. In this study,
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Highlights of the Year in JACC 2005 January 1, 2006:184–202ronounced hemodynamic benefit as well as favorable elec-
rical and mechanical changes in heart function were found
n this diverse group, most of whom underwent resynchro-
ization for congenital heart disease. It is a very different
ubstrate from the adult population, and more organized
rospective studies are to be very much anticipated.
etection of LV asynchrony in patients with right bun-
le branch block after repair of tetralogy of Fallot using
issue Doppler imaging derived strain. Tissue Doppler
maging derived strain was used to study LV contraction in
5 patients who had undergone tetralogy of Fallot repair
nd, as a result of surgery, had right bundle branch block
77). In tetralogy patients, the strain was statistically lower
han in the normal patients in all of the LV segments, and
he peak strain was most significantly delayed in the
id-septal segment. The study conclusion is that LV
synchrony in patients with tetralogy of Fallot and right
undle branch block is associated with decreased global
easures of LV function.
ffects of long-term bosentan in children with pulmo-
ary arterial hypertension. An important long-term study
f bosentan in congenital heart patients was published (78).
ata on Bosentan therapy in children before this study were
xtremely limited. This was an open label study involving 19
hildren with the safety and efficacy compared with adult
atients from recent studies. In 12 to 25 months, 36 patients
mproved by at least one class, 5 by two functional classes,
4 patients remained in the same functional class, and 8
orsened. The improvement was more pronounced for
hose who started bosentan without a concomitant prosta-
oid therapy. Fatigue led to discontinuation of bosentan in
patients and there were (asymptomatic) increases in liver
ransaminases in 10 patients. The data suggest that an oral
ndothelin receptor antagonist with or without prostanoid
herapy can be safe and efficacious in pulmonary artery
ypertension in children. An accompanying editorial by Ian
datia (79) concludes that these results show the effect of
osentan when administered to children in a dedicated
ulmonary hypertension center but questions whether this
an be reproduced in centers that are less organized and
xperienced.
ong-term outcome of transcatheter secundum-type
SD closure using Amplatzer septal occluders. Long-
erm follow-up of secundum ASDs closed with Amplatzer
eptal occluders was reported from Masura et al. (80) in 151
atients. There were no deaths, perforations, embolizations,
r malposition thrombus formation or significant arrhyth-
ias in the follow-up period ranging from 56 to 108
onths. Thirty-one patients had immediately detectable
hunts on transesophageal color Doppler echocardiography,
f which 7 remained at one month. There was no evidence
f encroachment on mitral or tricuspid valves, pulmonary
eins, or coronary sinus. All patients were maintained on the
nfective endocarditis prophylaxis for six months and aspirin
mg/kg/day. The group chosen to go to the cath lab was
elected from 190 patients consecutively found to have Tecundum ASD and therefore implantation was successful
n 79% of the ASD patients encountered during this period.
he authors stress precise selection of patients, based on
SD size compared with devices available as well as
ttention to detail and the use of transesophageal echocar-
iography during implantation.
NTERIOR MI
ri Ben-Yehuda, MD
hereas data support the superiority of primary PCI over
hrombolytic therapy for ST-segment elevation MI, the past
ear has seen a renewed emphasis on reducing door to
alloon times. A pivotal study by Bradley et al. (81)
xamined how 11 top-performing hospitals (based on data
rom the National Registry of Myocardial Infarction)
chieved door to balloon times of 90 min over a four-year
eriod. They identified pre-hospital ECG performed by
aramedics in the field (allowing emergency physicians to
ctivate the catheterization laboratory) as well as collabora-
ion between different departments in the hospital as pivotal
o the success of top-performing hospitals. Once patients
ith AMI are admitted, new data show the continued
mplementation of guideline-based standardized care can
elp ensure better outcome. The American College of
ardiology’s own Guidelines Applied in Practice projects in
ichigan demonstrated (82) that embedding AMI guide-
ines reduced mortality compared with historical controls by
1% to 26% even after multivariate adjustment. This re-
arkable benefit extended to 30-day and 1-year data.
A particularly vexing problem has been the patient with
MI complicated by cardiogenic shock, with historical
ortality rates of 60% to 70%. Although the SHOCK
SHould we emergently revascularize Occluded Coronaries
or cardiogenic Shock) trial demonstrated a reduction in
ortality to 51% at three months with revascularization, it
emained unclear whether the quality of life of survivors was
dequate. Sleeper et al (83) conducted interviews with
urviving SHOCK study patients. They demonstrated that,
hereas survival at one year with emergency revasculariza-
ion was only 46%, close to 90% of patients were in New
ork Heart Association (NYHA) functional class I or II
nd emergency revascularization patients had less functional
eterioration than patients assigned to medical stabilization.
he findings emphasize the importance of early revascular-
zation to improve not only mortality but also quality of life
84).
Whereas the aforementioned studies presented data up to
ne year after the event, the passing of several decades since
he institution of modern reperfusion therapy has allowed
omburg et al. (85) to present 20-year follow-up data on
33 patients enrolled from 1981 to 1985 in a study of
eperfusion (intracoronary streptokinase with some patients
lso receiving intravenous streptokinase and/or angioplasty
or severe residual stenosis) versus conventional treatment.
he authors demonstrated significant long-term survival
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5-, and 20-year survival being 69%, 48%, and 37%,
espectively, for the reperfusion group compared with 59%,
8%, and 27% for the conventional therapy group.
etabolic syndrome. The metabolic syndrome continued
o be a focus of multiple studies. With the obesity and
iabetes epidemic now extending into an ever younger age
roup, an important question is whether the presence of the
etabolic syndrome in young adults is also associated with
ncreased atherosclerosis. Tzou et al. (86) reported data
rom the Bogalusa Heart Study, a study of atherosclerosis in
he young. With ultrasound carotid intima-media thickness
easurements, the authors showed that among asymptom-
tic subjects the presence of the metabolic syndrome (de-
ned either by the National Cholesterol Education Program
dult Treatment Panel III or the World Health Organiza-
ion criteria) predicted composite carotid intima-media
hickness in the upper quartile. Moreover, the higher the
umber of components of the metabolic syndrome, the
igher the composite carotid intima-media thickness (r 
.997, ptrend  0.001).
How common is the metabolic syndrome in patients with
I? Does the influence of the metabolic syndrome extend
o the post-MI period? With data from the GISSI-
revenzione trial from Italy, Levantesi et al. (87) examined
he effects of the metabolic syndrome in 11,323 patients
ith prior MI enrolled in the trail. They found that 29%
et criteria for the metabolic syndrome. Death and cardio-
ascular events were more common in the patients with
etabolic syndrome, with a 29% and 23% increased risk,
espectively.
nflammation and CAD. Inflammation and inflammatory
arkers, particularly CRP, continued to be the subject of
any reports this year in the Journal. Inflammation plays a
ole in the pathogenesis of the atherosclerotic plaque but
lso in plaque rupture (i.e., in the pathogenesis of ACS).
hile previous studies documenting increased inflamma-
ory markers from the non-infarct coronary arteries suggest
hat inflammation in ACS is a diffuse process, direct
istopathological data has been lacking. Mauriello et al.
88), with multiple coronary artery segments from autopsy
pecimens of 16 patients with AMI, 5 patients with stable
ngina, and 9 patients without cardiac cause of death,
ivided plaques into culprit lesions, vulnerable plaques, and
table plaques, using the American Heart Association ath-
rosclerosis classification. They found an average of 6.8 
.5 vulnerable plaques per patient in the AMI group
ompared with an average of 0.8  0.3 and 1.4  0.3 in the
table angina group and noncardiac patients, respectively.
oreover, on immunohistochemical staining, the AMI
roup showed more inflammatory infiltrates not only in the
ulprit lesion and the vulnerable plaques but also in the
table plaques. In the same issue, Tanaka et al. (89) reported
n IVUS evidence of multiple plaque rupture. They studied
5 infarct-related and 84 non–infarct-related arteries in 45
atients with first AMI. Intravascular ultrasound detected an additional 17 plaque ruptures in 11 patients (24%).
oreover, high sensitivity (hs)-CRP levels correlated with
he number of plaque ruptures. The results of these studies
ighlight the importance of systemic therapies (such as lipid
owering) aimed at plaque stabilization in patients with
MI, a point emphasized in an accompanying editorial by
eter Libby (90).
What happens to ruptured plaques that are not the culprit
esions in ACS? With coronary angioscopy, Takano et al.
1) followed 50 such plaques in 30 patients over 13  9
onths. They demonstrated slow healing (23% at 1 year)
ith increasing stenosis. Interestingly, serum CRP levels
ere lower in patients with healed plaques. In another
tudy, Inoue et al. (92) measured serum hs-CRP just
roximal and distal to the culprit lesion. They thus demon-
trated local release of CRP into the coronary circulation
rom vulnerable plaques. Moreover, they demonstrated a
ise in the trans-coronary gradient of hs-CRP after stenting.
f indeed CRP plays a direct role in plaque instability and
he inflammatory reactions after stenting, it may end up
eing not only a marker of risk but a direct target of therapy.
Given the evidence that hs-CRP levels are of prognostic
mportance both for development of CAD and recurrence
f events after MI, it is of interest to ascertain which
herapies and which risk factors are associated with in-
reased hs-CRP levels. In a Focus Issue dedicated to studies
rom the Pravastatin or Atorvastatin Evaluation and Infec-
ion Therapy-Thrombolysis In Myocardial Infarction
PROVE IT-TIMI) 22 trial, Ray et al. (93) reported on a
ross-sectional study of 2,885 patients from the study who
ere evaluated four months after enrollment. They found
he CRP levels were associated with increasing age, female
ender, body mass index, smoking, persistent elevated LDL
70 mg/dl, glucose110 mg/dl, low high-density lipopro-
ein, elevated triglycerides, and the intensity of statin
herapy.
In the PROVE IT-TIMI 22 study, patients who
chieved the lowest LDL levels (as well as the lowest CRP
evels) had the lowest event rate. Is there any evidence of
anger associated with low LDL levels? In another paper in
he Focus Issue, Wiviott et al. (94) present very reassuring
ata for patients who lower LDL levels (patients were
ivided into groups with on-treatment LDL levels of 40,
0 to 60, 61 to 80, 81 to 100, and 100 mg/dl). Patients
ith the lowest LDL levels had the lowest event rates
ithout any increase in muscle, liver, or retinal abnormali-
ies. The authors conclude that in patients with ACS who
chieve very low LDL levels, there is no need to lower the
oses of the statins to elevate these very low LDL levels.
spirin and anti-platelet therapies. The issues surround-
ng aspirin, clopidogrel, and anti-platelet therapies contin-
ed to generate multiple submissions to the Journal. Ferrari
t al. (95) in an Express Publication alerted us to the risk of
ithdrawing aspirin after stenting. Among 1,236 patients
ospitalized with ACS, they identified 51 patients in whom
spirin withdrawal occurred within 30 days of ACS presen-
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Highlights of the Year in JACC 2005 January 1, 2006:184–202ation. ST-segment elevation myocardial infarction was
ore common in these patients compared with the non–
spirin-withdrawal patients. Moreover, 20% of the aspirin-
ithdrawal ACS patients had stent thrombosis, and all of
hese were BMS patients with an average time since
tenting of 15.5  6.5 months.
Aspirin and clopidogrel resistance has emerged as an
mportant topic in cardiovascular medicine. Given the
idely varying estimates of aspirin resistance (and multiple
ests used to assess resistance) the field is a controversial one.
antry et al. (96), with assays that employ arachidonic acid
s the agonist (aspirin inhibits the cyclooxygenase enzyme
hat acts on arachidonic acid to ultimately produce throm-
oxane A2), found that among 223 patients compliant with
spirin, only 1 patient (0.4%) was resistant to aspirin
herapy.
A similar situation exists with clopidogrel. Most studies have
efined clopidogrel resistance as inadequate inhibition of aden-
sine diphosphate-induced platelet aggregation. Clopidogrel
ainly blocks the P2Y12 receptor that is involved in stabili-
ation of platelet aggregates. Labarthe et al. (97) therefore
ompared various platelet function tests in their ability to assess
latelet aggregation stability. They demonstrated that when
latelet aggregation stabilization was measured rather than
latelet peak aggregation (a function of the P2Y1 receptor),
ost patients were identified as responders, especially when
he test was performed in hirudin/PPACK (6% to 12%
ncidence of nonresponsiveness).
Further studies, particularly linking the various test re-
ults to clinical outcomes, will be necessary to fully solve the
spirin resistance and clopidogrel resistance controversies.
EART FAILURE
arry H. Greenberg, MD
ne of the more vexing problems for clinicians is the
anagement of mitral regurgitation in heart failure patients.
efining whether mitral regurgitation is the cause or con-
equence of heart failure is rarely straight-forward, and
ecisions about whether to attempt surgical correction are
ften difficult to make. There has been growing enthusiasm
or performing mitral valve annuloplasty (MVA) for heart
ailure patients who are considered to have secondary mitral
egurgitation based on reports that this procedure improves
emodynamics and symptoms; however, effects of MVA on
urvival are uncertain. In a report from the University of
ichigan, which has been a strong proponent of MVA, Wu
t al. (98) retrospectively analyzed the clinical course of a
arge cohort of consecutive patients with significant mitral
egurgitation and LV systolic dysfunction who were treated
t their institution. Of the 682 patients identified, 419 were
onsidered to be surgical candidates, and of these, 126
nderwent MVA. Overall, 41% non-MVA and 49% MVA
atients reached a component of the composite end point of
eath, LV assist device implantation, or UNOS status
-cardiac transplantation. With Cox regression analysis that tncluded MVA as a time-dependent covariate and propen-
ity scoring to adjust for differing probabilities of undergo-
ng MVA, the investigators found that CAD (hazard ratio
.80, blood urea nitrogen (hazard ratio 1.01), cancer (hazard
atio 2.77), and digoxin (hazard ratio 1.66) were associated
ith this composite end point. Angiotensin-converting
nzyme inhibitors (hazard ratio 0.65), beta-blockers (hazard
atio 0.59), mean arterial pressure (hazard ratio 0.98), and
erum sodium (hazard ratio 0.93) were all associated with a
eduction in risk. Mitral valve annuloplasty failed to predict
linical outcome, a finding that led the investigators to
onclude that there is no clearly demonstrable mortality
enefit conferred by MVA for significant mitral regurgita-
ion with severe LV dysfunction. In an accompanying
ditorial, Mehra and Griffith (99) raised the pivotal question
f whether these results were a consequence of the lack of
fficacy of the surgical approach or whether a different
urgical approach is needed and whether annuloplasty alone
s sufficient. They were in agreement with the investigators
hat this question was still unsettled and that it needs to be
ddressed by well-designed clinical trials assessing various
urgical approaches.
An issue that is fundamental to surgical repair of the
itral valve in heart failure patients is whether or not the
itral valve in patients with severe LV dysfunction and
econdary mitral regurgitation is structurally normal. To
etermine if this was the case, Grande-Allen et al. (100)
ssessed the pathology in what were considered to be
ormal mitral valves from 37 heart failure patients (23
ilated, 14 ischemic) who underwent cardiac transplanta-
ion. They found that these mitral valves had up to 78%
ore DNA (p 0.03), 59% more glycosaminoglycans (p
.02), and 15% more collagen (p 0.007) but 7% less water
p  0.05) than normal. Derangements in biochemical
easures were associated with the absence of anterior leaflet
edundancy (p  0.03), leaflet thickness and DNA concen-
ration (, p  0.003), annular diameter and chordal
ollagen (, p  0.03), and water concentration and both
eft atrial diameter (, p  0.008) and LV collagen
oncentration (, p  0.04). The presence of the biochem-
cal abnormalities in these mitral valves suggested that the
xtracellular matrix had been influenced by the altered
ardiac dimensions and were not entirely functional in
ature. The presence of structural changes such as those
escribed in this study could provide an explanation for the
ailure of MVA annuloplasty alone to alter survival in heart
ailure patients with secondary mitral regurgitation.
Many patients with end stage renal disease develop heart
ailure associated with a reduced LV ejection fraction
LVEF). Wali et al. (101) assessed the effect of kidney
ransplantation on LVEF in end stage renal disease patients
ith heart failure. A total of 103 renal transplant recipients
ith LVEF 40% and evidence of heart failure underwent
adionuclide ventriculography 12 months after transplant.
verall, mean ejection fraction increased from 31.6  6.7%o 52.2  12.0% (p  0.002) at 12 months after transplan-
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ad normalized after renal transplantation. A shorter dura-
ion of pre-transplant dialysis was a significant predictor of
ecovery of cardiac function. Moreover, after renal trans-
lantation, an ejection fraction above 50% was the only
ignificant factor associated with a lower risk of death or
eart failure hospital stay. These results suggest that end-
tage renal disease patients who develop the onset of heart
ailure due to LV systolic dysfunction should be counseled
or kidney transplantation as soon as the diagnosis of
ystolic heart failure is established.
Although the mechanism(s) responsible for the recovery
f cardiac function after renal transplant was not evaluated,
heppard et al. (102) evaluated the role of apoptosis for
redicting myocardial recovery in recent-onset cardiomyop-
thy. In a group of 20 patients with recent-onset heart
ailure, the mean LVEF improved from 0.28 at baseline to
.40 after six months. Overall, these investigators found that
he highest expression of genes associated with apoptosis
e.g., Fas and tumor necrosis factor receptor type 1) was
ssociated with a reduced likelihood of recovery of cardiac
unction, suggesting that apoptosis limits myocardial recov-
ry. Thus, apoptotic pathways represent potential therapeu-
ic targets to help potentiate recovery of cardiac function in
atients with recent-onset cardiomyopathy. Of interest is
he fact that these findings could also relate to recovery of
ystolic function after renal transplantation where perhaps
ialysis through as yet undefined pathways initiates apopto-
is in cardiac myocytes.
An issue of great concern is the lack of support for
eart failure programs within a medical system. Most
ospitals use cross sectional accounting methods based on
irect reimbursement fees, an approach favoring
rocedure-oriented specialties but failing to take into
ccount the incremental revenues generated by the re-
ruitment of heart failure patients to system. To address
his issue, Gregory et al. (103) computed cumulative
ecurrent rates of utilization, cost, and reimbursement for
ospital services as functions of time using reliability
odels in 82 heart failure patients referred for cardiac
ransplant evaluation at an academic medical center
ompared with those not transplanted. They found that
ean hospital stays and outpatient encounters per patient
t the end of the first year for those transplanted were 2.1
nd 11.9, respectively, compared with 1.1 and 6.0 for
hose not transplanted. The mean revenue and direct cost
er patient were $194,470 and $146,623, respectively, for
ransplanted patients and $43,587 and $33,424, respec-
ively, for non-transplanted patients. Overall, the first-
ear contribution margins per patient were $47,847 for
ransplanted and $10,163 for non-transplanted patients.
his analysis provides evidence that newly evaluated
atients for cardiac transplantation generate substantial
ncident demands for inpatient and outpatient services
ver a two-year follow-up, regardless of whether trans-
lant was performed. oLECTROPHYSIOLOGY
regory K. Feld, MD
he use of automatic implantable defibrillators (ICDs) for
revention of sudden death has increased dramatically in the
ast several years. The indications for implantation of ICDs
ave been tightly regulated however, including the require-
ent for a QRS duration 120 ms for reimbursement.
hus, a number of studies have been undertaken to deter-
ine the most robust predictors of risk for subsequent
udden or arrhythmic death to more precisely identify
atients who will benefit from ICD implantation. Two such
tudies were published in the Journal in 2005. The first,
ublished by Gehi et al. (104), was a meta-analysis of 19
tudies involving 2,608 subjects who underwent microvolt
-wave alternans (MTWA) testing for exercise-induced
TWA. This analysis demonstrated that an abnormal
TWA test was associated with a significantly increased
isk of developing subsequent ventricular arrhythmia events,
ith positive predictive value of 51% for a secondary event
in patients with a history of previous ventricular arrhyth-
ia) and 15% for a primary event. Among patients evalu-
ted for prediction of a primary event, in those with
ongestive heart failure an abnormal MTWA test had a
ositive predictive value of 20.9%, whereas in those who
ere post-MI an abnormal MTWA test had a positive
redictive value of only 6.0%. Among those with ischemic
r non-ischemic etiology of congestive heart failure, there
as no difference in positive predictive value (29.7% vs.
1.3%). The negative predictive value was high in all
opulations studied (86% to 99.4%). Relative risk ranged
rom 2.51 to 4.74 across all groups. Indeterminate MTWA
ests were included in the data in some studies but not
thers and did not provide a clear predictive value. They
onclude that a positive MTWA test had significant pre-
ictive value for subsequent ventricular arrhythmic events,
ith a nearly four-fold relative risk compared with a
egative test. The authors suggested that further study of
he combined predictive value of several methods of risk
tratification was warranted.
In the second study on risk stratification of patients for
CD implantation, Buxton et al. (105) retrospectively ana-
yzed data from the PainFreeRx II study, a randomized,
2-month follow-up study comparing efficacy of anti-
achycardia pacing versus shock therapy for ventricular
achycardia/ventricular fibrillation in patients receiving
CDs. This sub-study consisted of 431 of the 634 patients
ho had CAD and a standard 12-lead ECG suitable for
nalysis. Approximately one-half had an ICD for primary
revention and the other half for secondary prevention, of
hom 76% and 87%, respectively, had prior MI. The mean
jection fraction was 30% in both primary and secondary
revention groups. The principal finding was that during
ollow-up, neither the time to occurrence nor the frequency
f arrhythmic events identified by ICD interrogation dif-
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r 120 ms, independent of whether the indication was for
rimary or secondary arrhythmia prevention. Patients with
eft bundle branch block, despite QRS duration 120 ms,
ere actually less likely to experience arrhythmia than
atients with QRS duration 120 ms (9% vs. 23%, p 
.02). The authors did find, however, that total mortality
as greater in patients with QRS duration 120 ms (15%
s. 9%, p  0.047), although the cause of deaths was not
etermined in several cases. Furthermore, the overall posi-
ive predictive value of QRS duration for arrhythmic events
radually increased from 23% with QRS duration 80 ms to
0% with QRS duration 190 ms. Nonetheless, the authors
oncluded that there was no argument for basing ICD
mplantation on QRS duration of  or 120 ms, as is
urrently recommended by Medicare guidelines. The au-
hors acknowledged several limitations of the study, includ-
ng its retrospective nature, the short duration of follow-up,
nd lack of patients with advanced congestive heart failure,
ny of which could have affected study outcome.
Atrial fibrillation can cause stroke and congestive heart
ailure, is a major risk for mortality especially with conges-
ive heart failure, and accounts for increasingly large na-
ional health care costs. In 2005, several articles of interest
ere published on the role of inflammation in development
f AF and the role of angiotensin receptor blockers and beta
eceptor blockers in the prevention of AF. Malouf et al.
106) reported on their study of 67 patients with AF or
trial flutter undergoing cardioversion, in whom hs-CRP
evels were measured just before cardioversion. Patients with
ecent infection, ACS, or surgery were excluded. Patients
ith successful cardioversion were then followed for up to
ne month for evidence of arrhythmia recurrence docu-
ented by ECG. They observed that arrhythmia recurrence
as associated with a significantly higher CRP level (odds
atio 1.84, p  0.013), even after adjusting for age, gender,
nd arrhythmia duration. On multivariate analysis, CRP
evel was the only independent predictor of AF or atrial
utter recurrence (odds ratio 2.19, p  0.036). The authors
oncluded that inflammation was a risk factor for AF/atrial
utter and anti-inflammatory interventions may help main-
ain normal sinus rhythm after cardioversion.
An alternative, novel pharmacological approach to pre-
ent AF was provided in a study by Wachtell et al. (107),
ho analyzed data from the Losartan Intervention for
ndpoint reduction in hypertension (LIFE) study in a
ubset of 8,851 patients with hypertension and ECG-
ocumented LV hypertrophy and no AF history. Patients
ere randomized to treatment with once-daily losartan
ersus atenolol-based antihypertensive therapy. After
ollow-up of up to a mean of 4.8 years, it was determined
hat losartan therapy was associated with a 33% lower rate of
ew-onset AF, as identified on annual in-study ECGs,
ndependent of other risk factors determined by univariate
nalysis, including age, male gender, systolic blood pressure,
nd LV hypertrophy on ECG. Development of AF during chis study was associated with significantly increased risk of
ardiovascular events, fatal and non fatal stroke, and rate of
ospital stay for congestive heart failure. The authors
ropose that the mechanism by which losartin prevents
ew-onset AF is by a reduction in LV hypertrophy, which
as shown in previous LIFE sub-studies to be associated
ith increased left atrial size and risk of AF and stroke.
In another study of alternative pharmacological ap-
roaches to prevention of AF, McMurray et al. (108)
eported data from a sub-study of the Carvedilol Post-
nfarct Survival Control in Left Ventricular Dysfunction
CAPRICORN) study, in which 1,959 patients with re-
uced LV systolic function after AMI (98% of whom were
reated with an angiotensin-converting enzyme inhibitor)
ere randomized to either placebo or carvedilol treatment 3
o 21 days after AMI. After an average of 1.3 years
ollow-up, the incidence of AF/atrial flutter and ventricular
rrhythmias were determined by review of reported adverse
vents, however without ECG documentation. The authors
oted a significantly lower reported incidence of AF/atrial
utter in the carvedilol-treated group compared with the
lacebo treatment group (2.3% vs. 5.4%, p  0.0003). The
uthors concluded from this study that beta-blocker therapy
ay play a significant role, in addition to angiotensin-
onverting enzyme inhibitor therapy, in prevention of AF/
trial flutter after AMI.
Radiofrequency catheter ablation has been extensively
tudied recently as a minimally invasive curative treatment
f AF; however, there is controversy over the most effective
nd safest ablation techniques. Because pulmonary vein
solation (PVI) may be associated with PVI stenosis, alter-
ative methods have been proposed and tested, including
he so-called left atrial linear ablation and left atrial circum-
erential ablation techniques. The original basis for such an
pproach was provided by Cox et al. (109) in their descrip-
ion of the first surgical operation called the MAZE
rocedure, wherein the right and left atrium were surgically
ompartmentalized into areas too small to sustain AF. In
005, there appeared two reports in the Journal that raised
somewhat controversial notion that linear left atrial
blation alone, without necessarily isolating the pulmonary
eins, could prevent recurrence of AF.
In the first report, Tanner et al. (110) demonstrated in a
opulation of 129 patients undergoing intra-operative left
trial linear ablation, that after 3.6  0.4 years follow-up,
even-day continuous ECG monitoring in 30 patients
evealed the occurrence of atrial ectopic beats in all patients
nd atrial runs in 83% of patients but AF in only 13% of
atients. The authors concluded that elimination of the
riggers of AF, which predominately arise from the pulmo-
ary veins, was not essential for prevention of AF but could
lso be accomplished by elimination of the reentrant sub-
trate required for maintenance of AF.
In a similar approach, Lemola et al. (111) studied 60
onsecutive patients with paroxysmal (39 patients) or
hronic (21 patients) AF and performed percutaneous left
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January 1, 2006:184–202 Highlights of the Year in JACC 2005trial circumferential ablation with radiofrequency energy.
he ablation lesions included encircling lesions around the
ight and left pulmonary veins, a line between the circles,
nd a line from the mitral valve annulus to the left circle.
fter left atrial linear ablation, pulmonary vein conduction
as assessed to determine the percentage of pulmonary
eins isolated by the linear ablation technique. After left
trial circumferential ablation, in 48 (80%) patients one or
ore pulmonary veins remained electrically connected to
he left atrium. Despite this, at 11  1 months follow-up
here was no difference in the recurrence rate of AF, with 10
f 12 (83%) with complete PVI and 39 of 48 (81%) with
ncomplete PVI free of AF. Freedom from AF was not
elated to the number of pulmonary veins isolated either.
he principal drawback of left atrial circumferential ablation
s the occurrence of left atrial flutter, with reentry through
aps in the line, in 17% of patients, independent of PVI.
any left atrial flutters require repeat ablation. The authors
f this study also concluded that PVI may not be necessary
o prevent recurrence of AF but that left atria linear ablation
odifies the substrate responsible for maintaining AF, thus
reventing its recurrence. It is not clear from these studies
hether a combination of left atrial linear ablation plus PVI
ill provide better long-term suppression of AF, as these
tudies were not prospective and randomized.
Ventricular arrhythmias in the absence of structural heart
isease have generally been considered benign. Two recent
eports in the Journal however, have brought to light a more
alignant potential for some idiopathic ventricular arrhyth-
ias. In a study by Noda et al. (112), 16 patients with a
istory of spontaneous ventricular fibrillation and/or poly-
orphic ventricular tachycardia initiated by ventricular ec-
opy with a left bundle branch block morphology and
nferior axis consistent with a right ventricular outflow tract
rigin were evaluated among an overall population of 101
atients in whom radiofrequency catheter ablation was
eing performed for idiopathic RVOT tachycardia. The
uthors found that 5 patients presented with spontaneous
entricular fibrillation and 11 had prior syncopal episodes.
mbulatory ECG recordings revealed frequent isolated
entricular extrasystoles with a morphology similar to those
nitiating ventricular fibrillation or polymorphic ventricular
achycardia. The history of syncope was higher in patients
ith ventricular fibrillation/polymorphic ventricular tachy-
ardia, the QRS duration of the ventricular ectopic beats
as longer, and the cycle length of tachycardias was shorter.
blation of the origin of the triggering foci in the RVOT
liminated syncopal episodes and ventricular fibrillation
pisodes in all 16 patients over a mean follow-up of 54 39
onths. The authors concluded that not all idiopathic
entricular ectopy is benign, but that in a small percentage
f patients with ventricular fibrillation/polymorphic ventric-
lar tachycardia, an idiopathic focus may be the trigger and
an be cured by radiofrequency catheter ablation. This is a
ovel and unexpected observation that expands our knowl-
dge of this syndrome. aIn another study of patients with idiopathic ventricular
ctopy of RVOT origin, Takemoto et al. (113) demon-
trated that a small percentage of patients developed unex-
ected LV dysfunction. They observed 45 consecutive
atients who underwent radiofrequency catheter ablation
or frequent monomorphic premature ventricular contrac-
ions originating from the RVOT. These patients under-
ent echocardiographic evaluation and ambulatory ECG
onitoring at baseline, one day, and 6 or 12 months after
adiofrequency catheter ablation. The patients were grouped
y percent premature ventricular contractions (10%, 10%
o 20%, 20% of total beats); LVEF, LV end-diastolic and
nd-systolic dimensions, and NYHA functional class were
valuated for each of these subgroups. The authors found a
ignificant correlation between percent premature ventricu-
ar contractions and LVEF (r  0.56, p  0.0002) and a
ignificantly lower LVEF and higher LV end-diastolic and
nd-systolic dimensions and NYHA functional class (p 
.05) in patients with 20% premature ventricular contrac-
ions. The LVEF, LV end-systolic and end-diastolic di-
ensions, and NYHA functional lass were also noted to
ormalize after successful radiofrequency catheter ablation
ut continued to deteriorate in those with unsuccessful
blation. The authors concluded that idiopathic RVOT
ctopy, generally considered benign, may be associated with
ignificant ventricular dysfunction and symptoms that could
ltimately to heart failure in some patients. This is a finding
hat physicians should be aware of when evaluating a patient
ith heart failure, because it may be a curable cause.
Finally, bi-ventricular pacing or cardiac resynchronization
herapy has become an important intervention in patients
ith refractory congestive heart failure. Whereas there are
any controversial issues in biventricular pacing, the role of
trial pacing has received less attention. One article pub-
ished in the Journal in 2005 addressed the issue of atrial
acing site with optimal atrioventricular delay. In a report
y Bernheim et al. (114), 17 patients who underwent cardiac
esynchronization therapy were studied a mean of 10
onths (1 to 46 months) after implantation to determine
he effects of right atrial pacing with the dual-chamber
ode compared with no atrial pacing in the single-chamber
ode. After optimizing atrioventricular delay by timing LV
ontraction properly at the end of atrial contraction, the
cute hemodynamic effects were assessed by Doppler echo-
ardiography. The authors demonstrated that single-
hamber mode pacing improved intra-ventricular dyssyn-
hrony measured by septal-to-posterior wall motion delay
single-chamber mode 106 83 ms vs. dual-chamber mode
45 95 m, p 0.001), whereas inter-ventricular mechan-
cal delay was not different. In addition, single-chamber
ode pacing significantly prolonged rate-corrected LV
lling period (single-chamber mode 458  123 ms vs.
ual-chamber mode 371 94 ms, p 0.001) and improved
yocardial performance index (single-chamber mode 0.60
0.18 vs. dual-chamber mode 0.71 0.23, p 0.01). Theuthors concluded that avoidance of right atrial pacing
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Highlights of the Year in JACC 2005 January 1, 2006:184–202esults in better LV resynchronization and hemodynamic
mprovement and thus the single-chamber mode seems
uperior to dual-chamber mode pacing in patients under-
oing cardiac resynchronization therapy.
ENERAL CARDIOLOGY RESEARCH
ilbur Y. W. Lew, MD
rythropoietin (EPO), the hematopoietic cytokine that
egulates erythropoiesis, has been shown in recent preclin-
cal studies to reduce injury from myocardial ischemia-
eperfusion. It is unknown if this novel cardioprotective
ffect of EPO occurs in humans. Namiuchi et al. (115)
tudied 101 patients who had successful PCI within 12 h of
heir first AMI. Patients with high versus low serum EPO
evels (above vs. below median values, respectively) had
maller infarcts as measured by peak creatine kinase levels
nd cumulative creatine kinase release. Serum EPO, along
ith preinfarction angina and TIMI flow grade 2 after PCI
ere identified as independent predictors of cumulative
reatine kinase release in a stepwise multiple regression
nalysis. Although preinfarction angina was more common
n the high EPO group and was associated with smaller
nfarct size (a potential confounding factor), serum EPO
evel was also an independent predictor of cumulative
reatine kinase release in patients without preinfarction
ngina. This study does not distinguish whether elevated
ndogenous EPO reduced infarct size owing to cardiopro-
ective effects or whether this association merely represents
n epiphenomenon; however, these results set the stage for
uture clinical studies to determine whether EPO has
ardioprotective effects that may be useful for treating
atients with ischemic heart disease.
Statins reduce infarct size after ischemia-reperfusion,
hich has been attributed to the pleiotropic effect of
ctivation of phosphatidylinositol-3 kinase (PI3K) /Akt, a
ell survival signaling pathway. Mensah et al. (116) used a
at model to demonstrate that one or three days of 20 mg/kg
torvastatin before ischemia-reperfusion reduced infarct
ize, but this protective effect was lost after one or two weeks
f pretreatment. Chronic atorvastatin treatment increased
TEN (phosphatase and tensin homolog deleted on chro-
osome 10), a major inhibitor of PI3K; however, the loss of
ardioprotection with chronic therapy could be recovered by
cute treatment with 40 mg/kg of atorvastatin. This is
linically relevant because many patients who would benefit
rom the cardioprotective effects of statins are likely to be
lready receiving chronic statin therapy. Schulz (117), in an
ccompanying editorial comment, discusses the cell signal-
ng pathways that are differentially activated by acute versus
hronic statin therapy and how their interaction determines
hether or not there is cardioprotection. There is evidence
hat statins reduce infarct size in patients, but some of the
enefits may be related to a reduction in plaque volume
nd/or plaque stabilization that decreases the extent of
oronary microembolization. Future clinical studies are deeded to determine if patients on chronic statin therapy
ill benefit from acute statin therapy.
Endothelial progenitor cells (EPC) have been postulated
o repair vascular injuries to prevent endothelial dysfunction
nd the progression of atherosclerosis. Two studies in the
ournalexamine whether EPC are altered in conditions
ssociated with endothelial dysfunction and vascular disease.
n the first study, Heiss et al. (118) compared 20 young with
0 older (average age 20 and 61 years, respectively) healthy
ndividuals without cardiovascular risk factors. There was no
ifference in the number of circulating EPC, but the older
roup had diminished EPC function (measured by in vitro
urvival, migration, and proliferation) in association with
mpaired brachial artery endothelium-dependent flow-
ediated dilation. Endothelial progenitor cell proliferation
nd migration were independent predictors of flow-
ediated dilation. This suggests that endothelial dysfunc-
ion with aging may be related to reduced EPC function.
In the second study, with 51 subjects, Fadini (119) found
40% to 50% reduction in circulating EPC levels in patients
ith peripheral vascular disease or type 2 diabetes mellitus
ompared with a healthy control group. The EPC levels
ere even lower in patients with both diseases. The authors
ypothesized that vascular disease in diabetes mellitus may
e related to a reduction in EPC.
Goldschmidt-Clermont et al. (120) in an accompanying
ditorial comment, review the evidence that bone marrow
erived EPC are recruited to repair arterial injuries; this
oncept has caused a paradigm shift in vascular biology.
hey propose that the inflammatory factors, cytokines, and
rowth factors that recruit EPC can exacerbate arterial
amage and cause progression of atherosclerosis when the
PC response is inadequate, such as with a senescent bone
arrow. Current methodological limitations in identifying
PC from surface markers makes it difficult to interpret
tudies with disparate methods and difficult to discern how
ells with specific markers function in the arterial repair
rocess; however, there are rapid technological break-
hroughs in this nascent field that may lead to novel
herapeutic approaches that target EPC. This may have an
mpact on the approach to common clinical cardiovascular
onditions (e.g., aging, diabetes mellitus, and vascular dis-
ase), as suggested by the studies in this Journal.
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tem cell therapy and paracrine factors. Encouraging
esults from both animal and human studies suggest that
tem cell therapy may be a viable means of myocardial repair
fter MI. One potential major limitation of this strategy is
he viability of the transplanted cells. Genetically engineer-
ng stem cells before implantation has been explored as an
ption to enhance their survival, proliferative capacity, and
unction. Tang et al. (121) engineered adult bone marrow
erived mesenchymal stem cells with the heme oxygenase 1
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ardioprotective properties via its antioxidant properties
reventing heme from causing oxidative injury, inflamma-
ion, and apoptosis. These cells were injected into mice one
after MI; their survival was enhanced five-fold at seven
ays, and myocardial function and remodeling was en-
anced at two weeks compared with animals that received
on-modified mesenchymal stem cells. This study not only
as evolved the methods for effective myocardial regenera-
ion and repair, it lends support to a growing body of
vidence that paracrine factors (e.g., HO-1) from mesen-
hymal stem cells may be in part responsible for the
eparative process.
iabetes and angiogenesis. Type II diabetic patients suf-
er a number of abnormalities of angiogenesis, including
nhanced vessel growth in the retina and the walls of
therosclerotic blood vessels, possibly leading to plaque
estabilization. The hearts of diabetic patients with chronic
oronary heart disease exhibit decreased collateral circula-
ion; however, paradoxically circulating levels of vascular
ndothelial growth factor are increased. Sasso et al. (122)
xamined the expression and function of vascular endothe-
ial growth factor in diabetic and non-diabetic patients
ndergoing coronary artery bypass surgery and found that
ascular endothelial growth factor levels in the myocardium
f diabetic patients was significantly increased whilst the
xpression levels of vascular endothelial growth factor re-
eptors (Flt-1 and Flk-1) were decreased. Moreover, acti-
ation signaling downstream of the vascular endothelial
rowth factor receptors was markedly reduced, as were a
umber of downstream effectors, such as endothelial nitric
xide synthase. Thus, this report provides key data that
egin to explain the seemingly paradoxical augmented
ascular endothelial growth factor levels and pro-angiogenic
ffects in some tissues but the defective signaling and
educed angiogenesis in the myocardium. Moreover, it
ocuses the therapeutic direction into the cell and perhaps at
pecific pathway targets for the treatment of diabetic pa-
ients with chronic cardiovascular disease.
PO and neovascularization. A number of cytokine
rowth factors are being investigated for their salutary
yocardial effects. Erythropoietin has been long known to
e expressed both inside and outside the hematopoietic
ystem, including in endothelial cells and cardiomyocytes.
an der Meer et al. (123) studied the role of early, early and
ate, and late erythropoietin treatment of rats with and
ithout MI. The results revealed a striking reduction in
nfarct size and improvement in myocardial function in rats
reated early and salutary effects on LV performance in
nimals treated late. Possible mechanisms include a reduc-
ion in cardiomyocyte loss due to EPO’s anti-apoptotic
ffects as well as an increase in myocardial capillary density
nd an increased capillary-to-myocyte ratio that was more
ronounced in the EPO-treated animals. Thus, this study is
mong the first to have shown a pronounced and significantalutary effect of EPO on the myocardium after infarction
nd suggests that further studies of EPO are warranted.
hocolate, flavonoids, and endothelial dysfunction. Is it
ossible that chocolate might acutely reverse some of the
oxious cardiovascular effects of smoking? It is well known
hat cigarette smoking causes a decrease in the bioactive
itric oxide (NO) in plasma and that this is associated with
ndothelial dysfunction as measured by flow mediated
ilation. Some studies have suggested that diets rich in
avonol might increase bioactive NO in plasma. Heiss et al.
124) studied the effects of a flavonol-rich cocoa preparation
n the circulating plasma NO and flow-mediated dilation in
mokers and showed a dose response between flavonol
ontent and acute increase in circulating NO and flow-
ediated dilation after oral ingestion of the cocoa drink.
hus, there may be some health benefits of flavonol-rich
oods such as cocoa (91).
eprint requests and correspondence: Dr. Anthony N. De-
aria, Cardiology Division, UCSD Medical Center, 200 West
rbor Drive, San Diego, California 92103-8411. E-mail:
demaria@usd.edu.
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